)
Visual
earnings real time
Ligand Pharmaceuticals (LGND) investor relations material
Ligand Pharmaceuticals Investor Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor Day 2025 summary9 Dec, 2025
Strategic evolution and business model
Shifted to a royalty-focused, operationally light model in 2022, reducing OpEx by over 50% and scaling investment capacity.
Business model leverages low-cost infrastructure, high operating leverage, and diversified exposure to biotech, with reinvestment compounding returns.
Special situations and flexible deal structures, including project finance and royalty monetization, are core to sourcing proprietary opportunities and enhancing returns.
Partnerships with leading pharmaceutical companies and platform investments like CaptisolⓇ and NITRICIL™ support broad applicability and revenue growth.
Maintains a lean infrastructure, generating $5M core revenue and $4M cash operating profit per employee.
Financial performance and guidance
Core revenue grew from $108M in 2022 to an expected $225–$235M in 2025, with projections of $245–$285M in 2026 and over $430M by 2030.
2025 guidance: $225M–$235M core revenue, $147M–$157M royalty revenue (~40% YoY growth), and adjusted EPS of $7.40–$7.65.
2026 guidance: $245M–$285M total revenue, $200M–$225M royalty revenue, and adjusted core EPS of $8.00–$9.00.
Five-year outlook projects a 23% CAGR in royalty receipts through 2030, driven by outperforming assets and new transactions.
Nearly $1B in deployable capital supports $150M–$250M annual investments and a robust pipeline.
Portfolio and investment activity
Portfolio includes 12 major commercial royalty drivers and over 80 development-stage programs, with key assets Filspari (9% royalty), Ohtuvayre (3%), Capvaxive, Qarziba, and Zelsuvmi (13%).
Filspari and Ohtuvayre expected to generate ~$200M in combined royalties by 2030.
Special situations like Pelthos and Apeiron have generated significant value, with Pelthos moving from bankruptcy to a $300M market cap and strong early launch of Zelsuvmi.
Investment team expanded from 3 to 18 since 2022, reviewing over 175 investments in 2025 and closing 6 deals, with $130M invested in 2025.
Q4 2025 pipeline includes 30+ actionable opportunities representing over $1B in potential investments.
What types of investments will drive 23% royalty CAGR?
What bridges the 20% to 23%+ royalty CAGR outlook?
Future revenue contribution from proprietary platforms?
Expand on proprietary deal flow in special situations
How will new investments mitigate portfolio concentration
How to leverage capital in inefficient development market
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ligand Pharmaceuticals earnings date
Q4 202527 Feb, 2026
Next Ligand Pharmaceuticals earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing innovative technologies and drug discovery platforms to pharmaceutical companies. Ligand’s business model centers around partnerships, where it provides proprietary drug development technologies such as its OmniAb antibody discovery platform and Captisol drug formulation technology. These technologies are used to support the development of therapies across a wide range of therapeutic areas, including oncology, infectious diseases, and autoimmune disorders. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage